Dafalgan 500 mg
- Substance
- Paracetamol
- Strength
- 500 mg
- Form
- tablet
- Pack
- 20 tablets
DATA MODEL AND METHODOLOGY
Connect medicine data across countries.
Medimapper preserves each source record, links local substances to a shared international identity and places normalised product attributes alongside the original values. Products remain separate; their relationship is calculated dynamically.
IDENTITY BEFORE COMPARISON
We do not match product names to product names.
Names are useful search terms, but not a reliable international identity. Medimapper first connects the active substance through maintained evidence. It then compares normalised strength, pharmaceutical form, pack and commercial identifiers while retaining the original source values.
- National source record
- Local substance recognition
- Shared substance identity
- Normalised presentation
- Pack and commercial identifiers
- Dynamic comparison
LOCAL RECORDS REMAIN TRACEABLE
Every product keeps its country and source context.
Each country has its own source-processing logic. A product continues to represent one record from one country and one applicable source.
- Local product and substance names
- National codes such as CNK, PZN, CIP or NDC
- Strength and pharmaceutical form
- Manufacturer, supplier or authorisation-holder information
- Pack configurations and GTINs
- Prices and reimbursement context
- Product status, source links and processing information
Fields are retained where the applicable source provides them.
THE INTERNATIONAL CONNECTION LAYER
Connect local substance concepts through maintained evidence.
Strong identity evidenceInChIKey · UNII · PubChem · applicable EMA SPOR references
Maintained conceptsSNOMED CT concepts and other governed reference mappings where applicable
Names and languageINNs · translations · synonyms · controlled handling of salt forms
Controlled proposalsCautious heuristic proposals that support review only
Cautious heuristic proposals can support review but do not automatically override conflicting identity evidence.
ORIGINAL VALUES IN, COMPARABLE VALUES ALONGSIDE THEM
Reduce false differences without pretending the records are the same.
The source value is never discarded. Normalisation makes comparison possible while the local expression remains available for verification.
| Attribute | Original source value | Normalised value |
|---|---|---|
| Strength | 0.5 g / 500 MG | 500 mg |
| Form | comprimé / Tablette | tablet |
| Pack | 3 × 10 tablets | 30 tablets |
FOUR TRANSPARENT MATCH LEVELS
See which attributes support the relationship.
01
Substance match
The products connect to the same active-substance identity. Strength, form and pack may differ.
Aligns on: substance identity
02
Presentation match
The substance identity, normalised strength and pharmaceutical form align.
Adds: normalised strength and form
03
Pack match
The presentation aligns and normalised pack size and configuration also match.
Adds: pack size and configuration
04
Commercial item match
The products share an applicable commercial identifier, such as a GTIN, where the identifier can be compared.
Adds: shared commercial identifier
SAME PRESENTATION, DIFFERENT PACK
Dafalgan and Doliprane align at presentation level, not pack level.
The shared substance identity, normalised strength and pharmaceutical form align. The pack size remains different and visible.
Substance match YesPresentation match YesPack match No
Doliprane 0.5 g
- Substance
- Paracétamol
- Strength
- 0.5 g
- Form
- comprimé
- Pack
- 16 tablets
USE THE RESULT WITH ITS CONTEXT
Coverage, source quality and intended use remain part of the answer.
Available fields and source depth vary by country. Medimapper keeps the path back to the source and states material limitations where known. Users remain responsible for validating the result for their clinical, regulatory, quality, legal or commercial use case.
REVIEW THE DATA ON A REAL EXAMPLE